Rabbit Polyclonal Kappa Opioid Receptor antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 3 publications.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA
WB | ICC/IF | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Tested |
Chimpanzee | Predicted | Predicted | Predicted |
Gorilla | Predicted | Predicted | Predicted |
Orangutan | Predicted | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Chimpanzee, Gorilla, Orangutan | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Chimpanzee, Gorilla, Orangutan | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Chimpanzee, Gorilla, Orangutan | Dilution info - | Notes - |
Select an associated product type
G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
OPRK, OPRK1, Kappa-type opioid receptor, K-OR-1, KOR-1
Rabbit Polyclonal Kappa Opioid Receptor antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 3 publications.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
The Kappa Opioid Receptor also known as KOR or kappa receptors is a type of opioid receptor that plays an important role in the nervous system. It is a protein with an approximate mass of 43 kDa. This receptor mainly expresses in the human brain especially in regions involved in pain and stress responses such as the hypothalamus and thalamus. Kappa receptors are involved in modulating neurotransmitter release and can affect synaptic transmission.
Kappa opioid receptors mediate pain perception mood regulation and stress response. They form part of a larger receptor family the G-protein coupled receptors (GPCRs) which are critical in cellular signaling. Activation of these receptors can produce analgesic effects differing from other opioid receptors due to their unique mechanism of action. Kappa receptors interact with endogenous ligands called dynorphins which are peptide neurotransmitters involved in natural pain relief processes.
Kappa opioid receptors are integral to the dopaminergic and serotonergic pathways. In the dopaminergic pathway kappa receptors reduce dopamine release influencing the reward system and potentially affecting addiction behaviors. In the serotonergic pathway they modulate serotonin levels connecting to mood and anxiety regulation. These pathways also involve proteins like the mu-opioid receptor and delta-opioid receptor which along with kappa receptors form a complex regulatory network.
Kappa opioid receptors have been linked to depression and drug addiction. In depression dysfunctional kappa receptor activity may disrupt mood regulation contributing to depressive symptoms. The associated protein dynorphin plays a role in this condition by interacting with kappa receptors. In drug addiction these receptors influence the brain's reward circuits impacting addiction severity through altered dopamine signaling. Understanding kappa receptors can offer insights into new therapeutic approaches for these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab113533 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - Anti-Kappa Opioid Receptor antibody (ab113533) at 1 µg/mL
Lane 1: Human brain tissue lysate - total protein at 10 µg
Lane 2: Human spinal cord tissue lysate - total protein at 10 µg
Lane 3: Human placenta tissue lysate - total protein at 10 µg
All lanes: Goat Anti-Rabbit IgG H&L (HRP) preadsorbed at 1/50000 dilution
Performed under reducing conditions.
Predicted band size: 42 kDa
Observed band size: 42 kDa, 52 kDa
Exposure time: 3min
ab113533 stained SKNSH cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab113533 at 5μg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43μM.
IHC image of Kappa Opioid Receptor staining in Human normal placenta formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab113533, 5μg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com